舒泰神(300204) - 2025 Q3 - 季度财报

Financial Performance - Revenue for Q3 2025 was ¥54,941,098.61, a decrease of 30.10% compared to the same period last year[4] - Net profit attributable to shareholders was -¥6,053,967.38, a decline of 1.89% year-over-year[4] - The company reported a net cash flow from operating activities of -¥107,047,029.72, a decrease of 332.81% year-to-date[4] - Operating income decreased by ¥80,449,514.04, a decline of 30.82% attributed to reduced product sales[10] - Total operating revenue for the period was ¥180,538,395.51, a decrease of 30.8% compared to ¥260,987,909.55 in the previous period[34] - The net profit for the current period is -37,879,165.05, compared to -9,364,956.52 in the previous period, indicating a significant increase in losses[35] - Operating profit for the current period is -37,392,767.69, compared to -8,614,783.75 in the previous period, reflecting a worsening operational performance[35] - Total comprehensive income for the current period is -53,467,389.71, compared to 16,012,131.45 in the previous period, showing a substantial decline[36] - Cash flow from operating activities shows a net outflow of -107,047,029.72, compared to -24,733,298.84 in the previous period, indicating increased cash burn[38] Assets and Liabilities - Total assets increased to ¥1,263,925,202.35, reflecting a growth of 9.94% from the end of the previous year[5] - Total assets reached ¥1,263,925,202.35, up from ¥1,149,607,757.17, reflecting a growth of 9.9%[32] - Total liabilities increased to ¥404,224,404.94 from ¥232,846,415.32, a rise of 73.3%[32] - The company's total equity decreased to ¥859,700,797.41 from ¥916,761,341.85, a decline of 6.2%[32] Cash and Cash Equivalents - Cash and cash equivalents increased by ¥104,087,711.75, a rise of 193.07% due to new investments received[9] - Cash and cash equivalents increased to ¥157,998,891.79 from ¥53,911,180.04, representing a growth of 192.5%[30] - Cash and cash equivalents at the end of the period amount to 157,410,459.27, up from 42,731,525.34 in the previous period, reflecting improved liquidity[38] Accounts Receivable and Inventory - Accounts receivable increased by ¥11,722,383.16, up 8,071.18% primarily due to reduced bank acceptance bill payments[9] - Accounts receivable decreased to ¥33,804,624.73 from ¥38,928,239.79, a decline of 13.5%[30] - Inventory rose to ¥30,096,329.85 from ¥22,181,013.09, an increase of 35.9%[31] Expenses - Financial expenses surged by ¥4,721,576.68, an increase of 11,906.93% due to the recognition of financial liabilities related to share repurchase obligations[10] - Research and development expenses for the same period were 82.60 million yuan, down 24.99% from 110.13 million yuan in 2024[17] - Research and development expenses for the current period are 58,104,013.78, down from 77,690,259.04 in the previous period, suggesting a reduction in investment in innovation[35] - Sales expenses decreased to 89,004,469.80 from 114,566,444.96, indicating cost-cutting measures in sales operations[35] Tax and Other Income - Income tax expenses increased by CNY 79,212.36, a growth of 11,527.33% year-over-year, primarily due to accelerated depreciation of fixed assets leading to deferred income tax[11] - Other comprehensive income after tax changed from CNY 25,377,087.97 in the same period last year to CNY -15,588,224.66 this period, a change of CNY -40,965,312.63, representing a 161.43% change, mainly due to fair value changes of other equity instruments[11] - Cash received from sales of goods and services decreased by CNY 102,998,067.71, a decline of 38.75% year-over-year, primarily due to reduced product sales[11] - Cash received from tax refunds decreased by CNY 1,574,494.77, a decline of 89.44% year-over-year, mainly due to last year's receipt of tax refunds[11] - Cash received from other operating activities decreased by CNY 2,254,077.84, a decline of 42.93% year-over-year, primarily due to reduced cash flow from operating activities[11] - Cash received from investment income decreased by CNY 474,528.17, a decline of 93.42% year-over-year, mainly due to reduced income from other equity investments[11] - Cash received from the disposal of fixed assets increased by CNY 1,643,966.32, an increase of 1,007.76% year-over-year, primarily due to increased disposals of fixed assets[11] - Cash received from investments increased from CNY 0 to CNY 133,333,300.00, primarily due to investments received from Wuxi Jinyi Yuanli Equity Investment Partnership[11] - Cash received from borrowings increased from CNY 0 to CNY 41,644,342.43, primarily due to bank loans received this period[11] - Cash received from other financing activities increased by CNY 50,340,840.00, an increase of 308.35% year-over-year, mainly due to the disposal of partial subsidiary equity without losing control[11] Clinical Trials and Product Development - The STSA-1002 injection for acute respiratory distress syndrome showed preliminary efficacy with a 28-day all-cause mortality rate of 26.67% in the low-dose group, compared to 40.00% in the control group[22] - The BDB-001 injection for ANCA-associated vasculitis demonstrated a 12-week partial remission rate of 76.5% in the high-dose group, comparable to the standard treatment group[23] - The overall incidence of serious adverse events for BDB-001 was 24.7%, with the lowest rate in the low-dose group at 6.3%[23] - The company plans to advance the Phase III clinical trial for BDB-001 based on current data indicating significant clinical benefits[23] - The STSP-0902 eye drops showed good safety and tolerability in healthy subjects, supporting further clinical trials in patients with neurotrophic keratitis[24] Corporate Governance and Plans - The company announced a board meeting to elect a non-independent director, maintaining the number of independent directors at three[25] - The company approved a plan for a targeted stock issuance to specific investors during the board meeting held on September 8, 2025[25] - The company announced plans for a private placement of shares, pending approval from regulatory authorities[26] - The election of Mr. Zheng Hong as the employee representative director was confirmed, ensuring compliance with legal requirements[27] Audit and Reporting - The company has not undergone an audit for the third quarter financial report[39]